hero
Dermbits
Welcome to Dermbits! Watch short videos of KOLs answering your questions
What documentation details helps support approval for ruxolitinib cream?

Topical Therapies

What documentation details helps support approval for ruxolitinib cream?

Featuring Alexandra Golant, MD

Can EHR templates improve access for new therapies like ruxolitinib?

Topical Therapies

Can EHR templates improve access for new therapies like ruxolitinib?

Featuring Alexandra Golant, MD

What are common documentation mistakes that delay access to newer topicals?

Topical Therapies

What are common documentation mistakes that delay access to newer topicals?

Featuring Alexandra Golant, MD

What’s key to documenting steroid failure or intolerance clearly?

Topical Therapies

What’s key to documenting steroid failure or intolerance clearly?

Featuring Alexandra Golant, MD

How do you talk to patients when access issues delay treatment?

Topical Therapies

How do you talk to patients when access issues delay treatment?

Featuring Alexandra Golant, MD

What’s your top access tip for new clinicians balancing care and paperwork?

Topical Therapies

What’s your top access tip for new clinicians balancing care and paperwork?

Featuring Alexandra Golant, MD

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

Cutaneous Melanoma

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

Featuring Brent Moody, MD

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

Cutaneous Melanoma

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

Featuring Brent Moody, MD

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

Cutaneous Melanoma

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

Featuring Brent Moody, MD

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?

Cutaneous Melanoma

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?

Featuring Brent Moody, MD

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?

Cutaneous Melanoma

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?

Featuring Brent Moody, MD

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?

Cutaneous Melanoma

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?

Featuring Brent Moody, MD

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?

Cutaneous Melanoma

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?

Featuring Brent Moody, MD

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?

Cutaneous Melanoma

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?

Featuring Brent Moody, MD

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?

Cutaneous Melanoma

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?

Featuring Brent Moody, MD

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody

Cutaneous Melanoma

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody

Featuring Brent Moody, MD

What makes a sunscreen well formulated from both a clinician and patient perspective?

Sunscreen

What makes a sunscreen well formulated from both a clinician and patient perspective?

Featuring Heather Woolery-Lloyd, MD

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?

Sunscreen

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?

Featuring Heather Woolery-Lloyd, MD

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?

Sunscreen

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?

Featuring Heather Woolery-Lloyd, MD

What makes a sunscreen particularly effective for pigment protection or visible-light defense?

Sunscreen

What makes a sunscreen particularly effective for pigment protection or visible-light defense?

Featuring Heather Woolery-Lloyd, MD

What is Helioplex technology, and how does it improve stability and UV coverage?

Sunscreen

What is Helioplex technology, and how does it improve stability and UV coverage?

Featuring Heather Woolery-Lloyd, MD

Why does a higher SPF still matter in real-world use?

Sunscreen

Why does a higher SPF still matter in real-world use?

Featuring Heather Woolery-Lloyd, MD

What is your take on the role of antioxidants in photoprotection?

Sunscreen

What is your take on the role of antioxidants in photoprotection?

Featuring Heather Woolery-Lloyd, MD

What are your go-to strategies for improving sunscreen adherence in daily life?

Sunscreen

What are your go-to strategies for improving sunscreen adherence in daily life?

Featuring Heather Woolery-Lloyd, MD

Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage?

Sunscreen

Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage?

Featuring Heather Woolery-Lloyd, MD

Which common medications increase photosensitivity, and how should this shape your counseling?

Sunscreen

Which common medications increase photosensitivity, and how should this shape your counseling?

Featuring Heather Woolery-Lloyd, MD

How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin?

Acne

How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin?

Featuring Joshua Zeichner, MD

Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery?

Acne

Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery?

Featuring Joshua Zeichner, MD

What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection?

Acne

What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection?

Featuring Joshua Zeichner, MD

Are there specific ingredients or technologies that help balance acne treatment with barrier preservation?

Acne

Are there specific ingredients or technologies that help balance acne treatment with barrier preservation?

Featuring Joshua Zeichner, MD

What are hydrophobically modified polymers, and what role do they play in cleanser tolerability?

Acne

What are hydrophobically modified polymers, and what role do they play in cleanser tolerability?

Featuring Joshua Zeichner, MD

What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them?

Acne

What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them?

Featuring Joshua Zeichner, MD

What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology?

Acne

What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology?

Featuring Joshua Zeichner, MD

How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier?

Acne

How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier?

Featuring Joshua Zeichner, MD

What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies?

Acne

What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies?

Featuring Joshua Zeichner, MD

What is the "retinol sandwich" method for managing acne?

Acne

What is the "retinol sandwich" method for managing acne?

Featuring Joshua Zeichner, MD

What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg?

Actinic Keratosis

What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg?

Featuring Vishal Patel, MD, FAAD, FACMS

In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU?

Actinic Keratosis

In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU?

Featuring Vishal Patel, MD, FAAD, FACMS

How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately?

Actinic Keratosis

How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately?

Featuring Vishal Patel, MD, FAAD, FACMS

When might you choose tirbanibulin over 5-FU for AK field therapy?

Actinic Keratosis

When might you choose tirbanibulin over 5-FU for AK field therapy?

Featuring Vishal Patel, MD, FAAD, FACMS

How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy?

Actinic Keratosis

How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy?

Featuring Vishal Patel, MD, FAAD, FACMS

How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

Actinic Keratosis

How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

Featuring Vishal Patel, MD, FAAD, FACMS

What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life?

Actinic Keratosis

What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life?

Featuring Vishal Patel, MD, FAAD, FACMS

What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk?

Actinic Keratosis

What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk?

Featuring Vishal Patel, MD, FAAD, FACMS

How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis?

Actinic Keratosis

How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis?

Featuring Vishal Patel, MD, FAAD, FACMS

What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches?

Actinic Keratosis

What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches?

Featuring Vishal Patel, MD, FAAD, FACMS

Is home-based NB-UVB a challenge to prescribe for clinicians?

NB-UVB

Is home-based NB-UVB a challenge to prescribe for clinicians?

Featuring Jessica Kaffenberger, MD

What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device?

NB-UVB

What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device?

Featuring Jessica Kaffenberger, MD

What are the key benefits of home-based NB-UVB devices?

NB-UVB

What are the key benefits of home-based NB-UVB devices?

Featuring Jessica Kaffenberger, MD

Is home-based NB-UVB better suited for localized disease or widespread conditions?

NB-UVB

Is home-based NB-UVB better suited for localized disease or widespread conditions?

Featuring Jessica Kaffenberger, MD

Is home-based NB-UVB device setup difficult for patients?

NB-UVB

Is home-based NB-UVB device setup difficult for patients?

Featuring Jessica Kaffenberger, MD

How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists?

NB-UVB

How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists?

Featuring Jessica Kaffenberger, MD

How straightforward is the prescribing and enrollment process for at-home phototherapy?

NB-UVB

How straightforward is the prescribing and enrollment process for at-home phototherapy?

Featuring Jessica Kaffenberger, MD

Why has phototherapy declined in use, and are the main barriers clinical or logistical?

NB-UVB

Why has phototherapy declined in use, and are the main barriers clinical or logistical?

Featuring Jessica Kaffenberger, MD

What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit?

NB-UVB

What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit?

Featuring Jessica Kaffenberger, MD

What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy?

NB-UVB

What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy?

Featuring Jessica Kaffenberger, MD

What differentiates IL-13 from IL-4 in the progression of AD?

Atopic Dermatitis

What differentiates IL-13 from IL-4 in the progression of AD?

Featuring Charlie Dunn, MD

How do you identify and manage itch-dominant AD patients?

Atopic Dermatitis

How do you identify and manage itch-dominant AD patients?

Featuring Charlie Dunn, MD

How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools?

Atopic Dermatitis

How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools?

Featuring Charlie Dunn, MD

What role does proactive vs reactive therapy play in maintaining long-term disease control in AD?

Atopic Dermatitis

What role does proactive vs reactive therapy play in maintaining long-term disease control in AD?

Featuring Charlie Dunn, MD

What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD?

Atopic Dermatitis

What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD?

Featuring Charlie Dunn, MD

What are the long-term impacts of early-onset AD on child development and overall health?

Atopic Dermatitis

What are the long-term impacts of early-onset AD on child development and overall health?

Featuring Charlie Dunn, MD

Should patients with moderate AD by treated with systemic therapies earlier in disease progression?

Atopic Dermatitis

Should patients with moderate AD by treated with systemic therapies earlier in disease progression?

Featuring Charlie Dunn, MD

How can dermatologists identify and manage treatment resistance in patients with AD?

Atopic Dermatitis

How can dermatologists identify and manage treatment resistance in patients with AD?

Featuring Charlie Dunn, MD

What are the most effective ways to communicate realistic treatment expectations to patients with AD?

Atopic Dermatitis

What are the most effective ways to communicate realistic treatment expectations to patients with AD?

Featuring Charlie Dunn, MD

What challenges exist in assessing AD in patients with skin of color, and how can they be addressed?

Atopic Dermatitis

What challenges exist in assessing AD in patients with skin of color, and how can they be addressed?

Featuring Charlie Dunn, MD

Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab?

Atopic Dermatitis

Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab?

Featuring James Del Rosso, DO

Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options?

Atopic Dermatitis

Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options?

Featuring James Del Rosso, DO

How can dermatologists improve diagnostic accuracy for AD in skin of color?

Atopic Dermatitis

How can dermatologists improve diagnostic accuracy for AD in skin of color?

Featuring James Del Rosso, DO

What clinical features define an ideal patient profile for starting lebrikizumab?

Atopic Dermatitis

What clinical features define an ideal patient profile for starting lebrikizumab?

Featuring James Del Rosso, DO

Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve?

Atopic Dermatitis

Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve?

Featuring James Del Rosso, DO

Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy?

Atopic Dermatitis

Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy?

Featuring James Del Rosso, DO

What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids?

Atopic Dermatitis

What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids?

Featuring James Del Rosso, DO

What results were seen in the clinical trials for lebrikizumab regarding itch reduction?

Atopic Dermatitis

What results were seen in the clinical trials for lebrikizumab regarding itch reduction?

Featuring James Del Rosso, DO

What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab?

Atopic Dermatitis

What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab?

Featuring James Del Rosso, DO

What outcomes have been observed with monthly maintenance dosing of lebrikizumab?

Atopic Dermatitis

What outcomes have been observed with monthly maintenance dosing of lebrikizumab?

Featuring James Del Rosso, DO

How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment?

Atopic Dermatitis

How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment?

Featuring James Del Rosso, DO

What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment?

Atopic Dermatitis

What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment?

Featuring James Del Rosso, DO

How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis?

Eczema

How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis?

Featuring Brad Glick, DO, MPH

What are the major subtypes of CHE, and how can they be differentiated in clinical practice?

Eczema

What are the major subtypes of CHE, and how can they be differentiated in clinical practice?

Featuring Brad Glick, DO, MPH

When should dermatologists consider patch testing in patients with chronic hand eczema?

Eczema

When should dermatologists consider patch testing in patients with chronic hand eczema?

Featuring Brad Glick, DO, MPH

What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology?

Eczema

What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology?

Featuring Brad Glick, DO, MPH

How does delgocitinib differ mechanistically from other topical therapies used for CHE?

Eczema

How does delgocitinib differ mechanistically from other topical therapies used for CHE?

Featuring Brad Glick, DO, MPH

How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream?

Eczema

How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream?

Featuring Brad Glick, DO, MPH

What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation?

Eczema

What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation?

Featuring Brad Glick, DO, MPH

Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of?

Eczema

Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of?

Featuring Brad Glick, DO, MPH

Is routine lab monitoring required for patients on delgocitinib cream?

Eczema

Is routine lab monitoring required for patients on delgocitinib cream?

Featuring Brad Glick, DO, MPH

Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns?

Eczema

Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns?

Featuring Brad Glick, DO, MPH

What is the MyPath Melanoma test, and how does it work?

Cutaneous Melanoma

What is the MyPath Melanoma test, and how does it work?

Featuring Alexander Witkowski, MD, PhD

What types of melanocytic lesions is the MyPath test best suited for?

Cutaneous Melanoma

What types of melanocytic lesions is the MyPath test best suited for?

Featuring Alexander Witkowski, MD, PhD

What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test?

Cutaneous Melanoma

What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test?

Featuring Alexander Witkowski, MD, PhD

What is the turnaround time for results from the MyPath Melanoma test, and how are results reported?

Cutaneous Melanoma

What is the turnaround time for results from the MyPath Melanoma test, and how are results reported?

Featuring Alexander Witkowski, MD, PhD

Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance?

Cutaneous Melanoma

Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance?

Featuring Alexander Witkowski, MD, PhD

Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?

Cutaneous Melanoma

Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?

Featuring Alexander Witkowski, MD, PhD

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?

Cutaneous Melanoma

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?

Featuring Alexander Witkowski, MD, PhD

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?

Cutaneous Melanoma

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?

Featuring Alexander Witkowski, MD, PhD

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?

Cutaneous Melanoma

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?

Featuring Alexander Witkowski, MD, PhD

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?

Cutaneous Melanoma

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?

Featuring Alexander Witkowski, MD, PhD

What are the limitations of GEP testing in melanoma diagnosis?

Cutaneous Melanoma

What are the limitations of GEP testing in melanoma diagnosis?

Featuring Alexander Witkowski, MD, PhD

Are GEP tests meant to replace or supplement traditional pathology for melanoma?

Cutaneous Melanoma

Are GEP tests meant to replace or supplement traditional pathology for melanoma?

Featuring Alexander Witkowski, MD, PhD

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?

Cutaneous Melanoma

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?

Featuring Alexander Witkowski, MD, PhD

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?

Atopic Dermatitis

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?

Featuring Pearl Kwong, MD

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?

Atopic Dermatitis

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?

Featuring Pearl Kwong, MD

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?

Atopic Dermatitis

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?

Featuring Pearl Kwong, MD

What is lebrikizumab's safety profile?

Atopic Dermatitis

What is lebrikizumab's safety profile?

Featuring Pearl Kwong, MD

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?

Atopic Dermatitis

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?

Featuring Pearl Kwong, MD

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?

Atopic Dermatitis

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?

Featuring Pearl Kwong, MD

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong

Atopic Dermatitis

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong

Featuring Pearl Kwong, MD

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?

Atopic Dermatitis

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?

Featuring Pearl Kwong, MD

What are some limitations of traditional scoring/scaling systems in assessing AD severity?

Atopic Dermatitis

What are some limitations of traditional scoring/scaling systems in assessing AD severity?

Featuring Pearl Kwong, MD

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?

Atopic Dermatitis

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?

Featuring Pearl Kwong, MD

What is the i31-SLNB score, and how does it improve melanoma risk stratification?

Skin Cancer

What is the i31-SLNB score, and how does it improve melanoma risk stratification?

Featuring Jason Rizzo, MD, PhD

What are the key thresholds or risk categories within the i31-SLNB score?

Skin Cancer

What are the key thresholds or risk categories within the i31-SLNB score?

Featuring Jason Rizzo, MD, PhD

In what types or stages of melanoma is the i31-SLNB score most clinically useful?

Skin Cancer

In what types or stages of melanoma is the i31-SLNB score most clinically useful?

Featuring Jason Rizzo, MD, PhD

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?

Skin Cancer

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?

Featuring Jason Rizzo, MD, PhD

What are common patient questions or concerns about this type of genomic testing?

Skin Cancer

What are common patient questions or concerns about this type of genomic testing?

Featuring Jason Rizzo, MD, PhD

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?

Skin Cancer

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?

Featuring Jason Rizzo, MD, PhD

How has the 31-GEP test report evolved?

Skin Cancer

How has the 31-GEP test report evolved?

Featuring Jason Rizzo, MD, PhD

What are some of the barriers to adopting the i31-SLNB score in community dermatology practices?

Skin Cancer

What are some of the barriers to adopting the i31-SLNB score in community dermatology practices?

Featuring Jason Rizzo, MD, PhD

What is the long-term vision for GEP-guided melanoma staging?

Skin Cancer

What is the long-term vision for GEP-guided melanoma staging?

Featuring Jason Rizzo, MD, PhD

What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB?

Skin Cancer

What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB?

Featuring Jason Rizzo, MD, PhD

Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo?

Vitiligo

Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo?

Featuring Amy McMichael, MD

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Vitiligo

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

Featuring Amy McMichael, MD

Can ruxolitinib for vitiligo be used with therapeutic biologics?

Vitiligo

Can ruxolitinib for vitiligo be used with therapeutic biologics?

Featuring Amy McMichael, MD

How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo?

Vitiligo

How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo?

Vitiligo

How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo?

Vitiligo

How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo?

Vitiligo

What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo?

Featuring Amy McMichael, MD

What are the most common causes of drug-induced vitiligo?

Vitiligo

What are the most common causes of drug-induced vitiligo?

Featuring Amy McMichael, MD

Can vitiligo spontaneously resolve?

Vitiligo

Can vitiligo spontaneously resolve?

Featuring Amy McMichael, MD

How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo?

Vitiligo

How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo?

Featuring Amy McMichael, MD

How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne?

Acne

How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne?

Featuring Christopher Bunick, MD, PhD

How effective is sarecycline for managing truncal acne?

Acne

How effective is sarecycline for managing truncal acne?

Featuring Christopher Bunick, MD, PhD

Is sarecycline an appropriate option for pediatric and preteen patients with acne?

Acne

Is sarecycline an appropriate option for pediatric and preteen patients with acne?

Featuring Christopher Bunick, MD, PhD

What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics?

Acne

What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics?

Featuring Christopher Bunick, MD, PhD

Can sarecycline be combined with topical treatments or other systemic therapies?

Acne

Can sarecycline be combined with topical treatments or other systemic therapies?

Featuring Christopher Bunick, MD, PhD

How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship?

Acne

How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship?

Featuring Christopher Bunick, MD, PhD

Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne?

Acne

Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne?

Featuring Christopher Bunick, MD, PhD

What are the latest insights into the impact of hormonal fluctuations on acne severity?

Acne

What are the latest insights into the impact of hormonal fluctuations on acne severity?

Featuring Christopher Bunick, MD, PhD

How should dermatologists determine when to escalate from topical to systemic acne treatments?

Acne

How should dermatologists determine when to escalate from topical to systemic acne treatments?

Featuring Christopher Bunick, MD, PhD

How should acne treatments be adjusted for patients with sensitive or atopic skin?

Acne

How should acne treatments be adjusted for patients with sensitive or atopic skin?

Featuring Christopher Bunick, MD, PhD

What is the role of the IL-13 pathway in AD pathogenesis and treatment?

Atopic Dermatitis

What is the role of the IL-13 pathway in AD pathogenesis and treatment?

Featuring Dawn Merritt, DO

What is the relationship between itch improvement and overall AD control?

Atopic Dermatitis

What is the relationship between itch improvement and overall AD control?

Featuring Dawn Merritt, DO

What is the role of IL-13 in driving itch in AD?

Atopic Dermatitis

What is the role of IL-13 in driving itch in AD?

Featuring Dawn Merritt, DO

144 of 900